VEGF-A and angiopoietin-2 inhibitor bispecific antibody - MedImmuneAlternative Names: Ang-2-VEGF bispecific antibody - MedImmune
Latest Information Update: 02 Dec 2016
At a glance
- Originator MedImmune
- Class Bispecific antibodies
- Mechanism of Action Angiopoietin-2 inhibitors; Vascular endothelial growth factor A inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified